Perjeta

(Pertuzumab)

ApprovedMonoclonal antibody

Pertuzumab is used to treat certain types of breast cancer, particularly HER2-positive breast cancers. It works by blocking a protein that helps cancer cells grow and survive.[2] Perjeta is currently approved and in use across 32 indications[4].[1]

Perjeta is one of 450 biologic programs targeting Breast Cancer. It is currently in Approved.

Indications

235

Total Trials

Active Trials

449

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Breast CancerUnknown status

Neoadjuvant TreatmentNot yet recruiting

Metastatic Breast CancerActive, not recruiting

Breast NeoplasmUnknown

HER2 Positive Breast CarcinomaUnknown

Breast CarcinomaNot yet recruiting

Brain MetastasesActive, not recruiting

Anatomic Stage I Breast Cancer AJCC V8Recruiting

Advanced LymphomaActive, not recruiting

Malignant Solid NeoplasmActive, not recruiting

Breast CancerApproved

Unknown status

Neoadjuvant TreatmentPhase 2

Not yet recruiting

Metastatic Breast CancerPhase 3

Active, not recruiting

Breast NeoplasmPreclinical

Unknown

HER2 Positive Breast CarcinomaPreclinical

Unknown

Breast CarcinomaPhase 2

Not yet recruiting

Brain MetastasesPhase 2

Active, not recruiting

Anatomic Stage I Breast Cancer AJCC V8Phase 3

Recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Malignant Solid NeoplasmPhase 2

Active, not recruiting

Showing 10 of 32 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Perjeta

Blenoxane

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

2 6

Duragesic

CCephalon

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Breast Cancer

NCT02827877

Phase 2Active, not recruiting

Neoadjuvant Therapy

NCT04172259

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT06178159

Phase 1Active, not recruiting

Breast Cancer

NCT02057133

Phase 2Recruiting

Breast Cancer

NCT05891561

Phase 2Recruiting

Neoadjuvant Treatment

NCT07335081

Clinical

Trials by Indication[1]

Breast Cancer141 trials

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Unknown status·SShanghai Pudong Hospital·N/A·NCT05656079·204 enrolled

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT03674112·160 enrolled

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01276041·70 enrolled

Show 138 more trials

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Completed· Roche logo

Roche·Phase 1·NCT02738970·88 enrolled

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Completed·—·Phase 2·NCT02789657·32 enrolled

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06278870·312 enrolled

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06686394·81 enrolled

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02491892·79 enrolled

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Terminated·UUS Oncology Research·Phase 2·NCT02229149·33 enrolled

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT04329065·25 enrolled

Fasting on Newly Diagnosed Breast Cancer

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02379585·8 enrolled

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01358877·4,804 enrolled

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Completed· Roche logo

Roche·Phase 2·NCT00943670·51 enrolled

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01674062·95 enrolled

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Unknown status·NNSABP Foundation Inc·Phase 2·NCT03412643·64 enrolled

De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer

Active, not recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07421141·186 enrolled

A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01565083·213 enrolled

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Active, not recruiting·—·Phase 2·NCT01730833·63 enrolled

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02132949·401 enrolled

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT02514681·226 enrolled

Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

Active, not recruiting·HHelsinki University Central Hospital·Phase 3·NCT02625441·516 enrolled

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Withdrawn·IiOMEDICO AG·Phase 3·NCT03811418

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Terminated·BBolt Biotherapeutics, Inc.·Phase 2·NCT05954143·11 enrolled

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Completed·—·Phase 2·NCT01959490·16 enrolled

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Completed·UUNICANCER·Phase 2·NCT02339532·86 enrolled

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·N/A·NCT01048099·283 enrolled

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03726879·454 enrolled

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Withdrawn·UUniversity of Rochester·Phase 2·NCT04419181

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT07393425·50 enrolled

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT05180006·33 enrolled

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Terminated·RRenske Altena·Phase 2·NCT03894007·6 enrolled

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT02003209·315 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Unknown status·MMidwestern Regional Medical Center·Phase 2·NCT02689921·7 enrolled

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT07371585·300 enrolled

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Completed·WWest German Study Group·Phase 2·NCT03988036·46 enrolled

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Completed· Roche logo

Roche·Phase 3·NCT02586025·329 enrolled

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not yet recruiting·—·Phase 2·NCT05983094·181 enrolled

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT03101748·34 enrolled

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03199885·190 enrolled

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Completed· Roche logo

Roche·Phase 1·NCT01918254·66 enrolled

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01597414·80 enrolled

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Completed·NNYU Langone Health·Phase 2·NCT03742986·8 enrolled

Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

Completed·VVejle Hospital·Phase 2·NCT02909751·80 enrolled

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Not yet recruiting·DDavid Garcia Cinca·Phase 2·NCT04301375·27 enrolled

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04024462·200 enrolled

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04900311·490 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT05415215·346 enrolled

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03493854·500 enrolled

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Completed·GGBG Forschungs GmbH·Phase 3·NCT02125344·961 enrolled

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Completed· Roche logo

Roche··NCT00833963·20 enrolled

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00301899·37 enrolled

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02060253·9 enrolled

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02131064·444 enrolled

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03329378·7 enrolled

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05159193·372 enrolled

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

Unknown status·IInstitut Català d'Oncologia··NCT05912062·80 enrolled

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07246317·188 enrolled

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06178159·40 enrolled

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT00951665·107 enrolled

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Completed· Roche logo

Roche·Phase 1/2·NCT00875979·67 enrolled

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Recruiting·UUniversity of Chicago·Phase 2·NCT06348134·74 enrolled

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02402712·418 enrolled

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Not yet recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT07220135·100 enrolled

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Not yet recruiting·RRenJi Hospital·Phase 2·NCT06510465·143 enrolled

Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT03820141·39 enrolled

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03125928·16 enrolled

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00976989·225 enrolled

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Recruiting·FFudan University·Phase 3·NCT05883852·1,406 enrolled

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Active, not recruiting·FFondazione Michelangelo·Phase 3·NCT03595592·650 enrolled

HB1801 Combined Treatment of HER2-positive Breast Cancer

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT07116824·80 enrolled

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Not yet recruiting·SShandong Cancer Hospital and Institute·Phase 4·NCT07093931·468 enrolled

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02896855·243 enrolled

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04538742·245 enrolled

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Completed· Roche logo

Roche·Phase 4·NCT02445586·52 enrolled

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Recruiting·SShengjing Hospital·Phase 2·NCT05638594·236 enrolled

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01491737·258 enrolled

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Completed·OOtto Metzger, MD·Phase 1·NCT02390427·68 enrolled

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04717531·60 enrolled

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting·NNational Institute of Oncology, Hungary··NCT05131893·300 enrolled

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02019277·50 enrolled

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07441460·1,800 enrolled

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Recruiting·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT05319873·18 enrolled

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

Recruiting·TThe Netherlands Cancer Institute·Phase 1·NCT06162559·30 enrolled

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05720026·560 enrolled

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT04629846·517 enrolled

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT05838066·880 enrolled

A Study for the Adjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420467·2,413 enrolled

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Completed· Roche logo

Roche·Phase 2·NCT02536339·40 enrolled

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT05041842·53 enrolled

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01875666·26 enrolled

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Completed·UUniversity of Washington·Phase 1/2·NCT01922921·31 enrolled

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Terminated·KKimberly Blackwell·Phase 1·NCT02598427·1 enrolled

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00545688·417 enrolled

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Active, not recruiting·BBioRay Pharmaceutical Co., Ltd.·Phase 3·NCT04514419·408 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Completed·YYale University·Phase 2·NCT01855828·50 enrolled

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

Unknown status·IInstitut fuer Frauengesundheit·Phase 4·NCT05036005·108 enrolled

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Terminated·—·Phase 2·NCT01912963·32 enrolled

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Recruiting·Wwang shusen·Phase 2·NCT05978648·116 enrolled

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Recruiting·—·Phase 2·NCT04993014·80 enrolled

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

Unknown status·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT03144947·65 enrolled

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02947685·518 enrolled

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Terminated·VVall d'Hebron Institute of Oncology·Phase 1·NCT05385705·2 enrolled

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

Completed·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT02411344·64 enrolled

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT02057133·198 enrolled

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Active, not recruiting·—·Phase 2·NCT02827877·18 enrolled

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Not yet recruiting·SShandong Cancer Hospital and Institute·N/A·NCT07187752·1,039 enrolled

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Completed·CCinnagen·Phase 3·NCT04957212·214 enrolled

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT04108858·2 enrolled

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Completed· Roche logo

Roche·Phase 3·NCT01026142·452 enrolled

Cardiac Safety Study in Patients With HER2 + Breast Cancer

Completed·MMedstar Health Research Institute·Phase 2·NCT01904903·31 enrolled

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07340398·200 enrolled

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00567190·808 enrolled

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02139358·15 enrolled

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT04253561·17 enrolled

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Active, not recruiting·FFudan University·Phase 3·NCT04193059·1,560 enrolled

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Completed· Roche logo

Roche·Phase 3·NCT01120184·1,095 enrolled

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

Completed·WWest German Study Group·Phase 2·NCT01817452·220 enrolled

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03135171·11 enrolled

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04398914·216 enrolled

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

Completed· Roche logo

Roche··NCT02266173·1,130 enrolled

A Study for the Neoadjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420454·1,576 enrolled

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05891561·120 enrolled

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Recruiting·KKarolinska University Hospital·Phase 2·NCT05900206·370 enrolled

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Unknown status·FFudan University·Phase 1/2·NCT05574881·72 enrolled

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01966471·1,846 enrolled

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Active, not recruiting·CCaigang Liu·Phase 2/3·NCT05426486·136 enrolled

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT04683445·80 enrolled

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting·BBaylor Breast Care Center·Phase 2·NCT05020860·185 enrolled

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04337658·493 enrolled

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT00934856·98 enrolled

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04760431·120 enrolled

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

Not yet recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT07402473·50 enrolled

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Unknown status·—·Phase 2·NCT04197687·480 enrolled

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01572038·1,436 enrolled

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute··NCT07470203·42 enrolled

Neoadjuvant Treatment4 trials

ctDNA in HER2+ EBC Neoadjuvant Treatment

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT07335081·60 enrolled

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07047755·48 enrolled

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Completed·GGBG Forschungs GmbH·Phase 2·NCT02682693·780 enrolled

Show 1 more trial

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06927180·180 enrolled

Ovarian Cancer3 trials

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Completed· Roche logo

Roche·Phase 2·NCT02004093·149 enrolled

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Completed· Roche logo

Roche·Phase 2·NCT00058552·129 enrolled

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Completed· Roche logo

Roche·Phase 3·NCT01684878·208 enrolled

Metastatic Colorectal Cancer3 trials

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00551421·17 enrolled

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Unknown status·FFondazione del Piemonte per l'Oncologia·Phase 2·NCT03225937·54 enrolled

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT02291289·1,044 enrolled

Non-Small Cell Lung Cancer3 trials

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT00855894·41 enrolled

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 1·NCT02507375·17 enrolled

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

Completed· Roche logo

Roche·Phase 2·NCT00063154·51 enrolled

36 more indications

Immunotherapy2 trials

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02345772·4 enrolled

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Immunogenicity2 trials

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Active, not recruiting·MMabscale, LLC·Phase 1·NCT05825781·114 enrolled

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Completed·ZZydus Lifesciences Limited·Phase 3·NCT05283837·268 enrolled

Gastric Cancer2 trials

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Completed· Roche logo

Roche·Phase 2·NCT01461057·30 enrolled

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Completed· Roche logo

Roche·Phase 3·NCT01774786·780 enrolled

Trial2 trials

The Sagittarius Trial

Recruiting·IIFOM ETS - The AIRC Institute of Molecular Oncology·Phase 3·NCT06490536·700 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Patients With Advanced Solid Tumors2 trials

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+

Terminated·MMichelle Melisko·Phase 1·NCT02593708·6 enrolled

Neoadjuvant2 trials

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated·JJules Bordet Institute·Phase 2·NCT04675827·139 enrolled

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT02073487·32 enrolled

Advanced Solid Tumors2 trials

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT02091141·673 enrolled

Paclitaxel2 trials

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Completed·—·Phase 2·NCT01796197·23 enrolled

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT03264547·446 enrolled

Cancer of Unknown Primary Site1 trial

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Completed· Roche logo

Roche·Phase 2·NCT03498521·529 enrolled

Esophageal Carcinoma1 trial

Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma

Completed·—·Phase 1/2·NCT02120911·40 enrolled

Fallopian Tube Cancer1 trial

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed· Roche logo

Roche·Phase 2·NCT00096993·131 enrolled

Carboplatin1 trial

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

Active, not recruiting·UUniversity of California, Irvine·Phase 2·NCT02436993·120 enrolled

Colorectal Cancer1 trial

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT03365882·240 enrolled

Completed·FFudan University··NCT05572645·333 enrolled

HER2 Positive1 trial

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Active, not recruiting·—·Phase 1·NCT03716180·100 enrolled

Dendritic Cell1 trial

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05325632·53 enrolled

Left Ventricular Dysfunction1 trial

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Recruiting·PPopulation Health Research Institute·Phase 2·NCT04680442·130 enrolled

Prostate Cancer1 trial

A Study of Pertuzumab in Participants With Prostate Cancer

Terminated· Roche logo

Roche·Phase 2·NCT02480010·68 enrolled

Neuroendocrine Cancer1 trial

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01121939·43 enrolled

DM11 trial

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Completed·SSwiss Cancer Institute·Phase 2·NCT01835236·208 enrolled

Vaccine1 trial

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02336984

Leptomeningeal Disease1 trial

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04588545·39 enrolled

Ptosis1 trial

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

Completed·FFondazione Michelangelo·Phase 2·NCT02530424·102 enrolled

Phase II1 trial

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Completed· Roche logo

Roche·Phase 2·NCT00096941·3 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

HER21 trial

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Active, not recruiting·—·Phase 2·NCT02326974·164 enrolled

Esophageal Cancer1 trial

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

Recruiting·—·Phase 3·NCT05188313·376 enrolled

Neoadjuvant Therapy1 trial

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04172259·156 enrolled

Pancreatic Adenocarcinoma1 trial

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Terminated·GGeorge Albert Fisher·Phase 2·NCT01108458·1 enrolled

HER2 Amplification1 trial

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting·CCancer Research UK·Phase 2/3·NCT05786716·30 enrolled

Neuroendocrine Tumors1 trial

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Terminated·—·Phase 2·NCT00947167·4 enrolled

PIK3CA-related Overgrowth Spectrum (PROS)1 trial

An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.

Not yet recruiting· Novartis logo

Novartis·Phase 2·NCT07679269·51 enrolled

Advanced HER2+Breast Cancer1 trial

EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT04208178·19 enrolled

Unspecified3 trials

NSABP Biospecimen Discovery Project

Unknown status·NNSABP Foundation Inc··NCT01850628·50 enrolled

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

MARGetuximab Or Trastuzumab (MARGOT)

Active, not recruiting·—·Phase 2·NCT04425018·174 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 8, 2012

PERJETA

BLA BLA125409

Sources

References

[1]
ClinicalTrials.gov — 235 trial records for Pertuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Perjeta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pertuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pertuzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA125409). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Receptor Protein-Tyrosine Kinase Erbb-2 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Perjeta

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Breast Cancer141 trials

Neoadjuvant Treatment4 trials

Ovarian Cancer3 trials

Metastatic Colorectal Cancer3 trials

Non-Small Cell Lung Cancer3 trials

Immunotherapy2 trials

Immunogenicity2 trials

Gastric Cancer2 trials

Trial2 trials

Patients With Advanced Solid Tumors2 trials

Neoadjuvant2 trials

Advanced Solid Tumors2 trials

Paclitaxel2 trials

Cancer of Unknown Primary Site1 trial

Esophageal Carcinoma1 trial

Fallopian Tube Cancer1 trial

Carboplatin1 trial

Colorectal Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Lung Cancer1 trial

Pyrotinib1 trial

HER2 Positive1 trial

Dendritic Cell1 trial

Left Ventricular Dysfunction1 trial

Prostate Cancer1 trial

Neuroendocrine Cancer1 trial

DM11 trial

Vaccine1 trial

Leptomeningeal Disease1 trial

Ptosis1 trial

Phase II1 trial

Treatment1 trial

HER21 trial

Esophageal Cancer1 trial

Neoadjuvant Therapy1 trial

Pancreatic Adenocarcinoma1 trial

HER2 Amplification1 trial

Neuroendocrine Tumors1 trial

PIK3CA-related Overgrowth Spectrum (PROS)1 trial

Advanced HER2+Breast Cancer1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News